No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection: Table 1. | Zendy

Mark Sulkowski | Zendy; WanLong Chuang | Zendy; JiaHorng Kao | Zendy; Jenny C. Yang | Zendy; Bing Gao | Zendy; Diana M. Brainard | Zendy; Kwang–Hyub Han | Zendy; Edward Gane | Zendy

Open Access

No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection: Table 1.

Author(s) -

Mark Sulkowski,

WanLong Chuang,

JiaHorng Kao,

Jenny C. Yang,

Bing Gao,

Diana M. Brainard,

Kwang–Hyub Han,

Edward Gane

Publication year - 2016

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciw507

Subject(s) - medicine , sofosbuvir , ledipasvir , virology , hepatitis b virus , hepatitis c virus , hepatitis c , virus , gastroenterology , ribavirin

Postmarketing cases of hepatitis B virus (HBV) reactivation during hepatitis C treatment have been reported. We analyzed serum samples from patients in a clinical trial of ledipasvir-sofosbuvir in Taiwan and Korea. Of the 173 patients enrolled, 103 (60%) had been previously infected with HBV. None showed evidence of HBV reactivation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research